Irinotecanhydrochlorid 3 H2o Kelix Bio

Irinotecan Hydrochloride Trihydrate, the active ingredient in Irinotecanhydrochlorid 3 H2O Kelix Bio, is a topoisomerase I inhibitor presented as an injectable solution for intravenous use. It treats colorectal cancer, including metastatic disease, in adult patients.

GNH USA supplies Irinotecanhydrochlorid 3 H2O Kelix Bio as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Irinotecan is a topoisomerase I inhibitor used in the management of colorectal cancer and related metastatic disease.

- Colorectal cancer: improves overall survival when used in combination chemotherapy. - Metastatic colorectal cancer: part of standard first‑line regimens for advanced disease. - Recurrent colorectal cancer: employed after disease progression on prior therapies.

Irinotecan may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Neutropenia: reduced white blood cell count increasing infection risk. - Diarrhea: may be severe and require supportive care. - Nausea and vomiting: typical chemotherapy‑related symptoms. - Alopecia: hair loss during treatment cycles. - Fatigue: generalized weakness and reduced stamina. - Abdominal pain: discomfort in the gastrointestinal tract.

Serious or Rare Side Effects: - Febrile neutropenia: fever with low neutrophil count requiring urgent medical attention. - Severe colitis: life‑threatening inflammation of the colon. - Allergic reactions: rash, itching, or anaphylaxis. - Hepatotoxicity: liver enzyme elevations indicating potential liver injury. - Pulmonary toxicity: rare lung inflammation or fibrosis. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Irinotecan requires careful monitoring and specific safety measures before and during therapy.

- Monitor blood counts: perform regular complete blood counts to detect neutropenia. - Assess liver function: check hepatic enzymes and bilirubin prior to each cycle. - Evaluate bowel status: screen for obstruction or severe diarrhea risk. - Adjust dose in hepatic impairment: reduce dosage according to liver function tests. - Avoid use in severe neutropenia: postpone treatment if neutrophils are critically low. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Irinotecan can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase SN‑38 exposure. - UGT1A1 inhibitors (e.g., atazanavir, indinavir): raise risk of severe neutropenia. - Concurrent myelosuppressive agents: additive bone‑marrow toxicity. - Live vaccines: heightened infection risk during immunosuppression. - Anticholinergic drugs: may exacerbate constipation and bowel complications.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): reduce therapeutic effect. - Antacids containing magnesium or aluminum: may alter gastrointestinal absorption. - Warfarin: monitor INR as irinotecan can affect anticoagulation control.